Corrigendum to "Risk of secondary myelodysplastic syndromes and acute myeloid leukaemia following poly(ADP-ribose) polymerase inhibitor treatment for advanced-stage ovarian cancer: A retrospective cohort study" [Eur J Cancer 222 (2025) 115472].
Steventon L., Nicum S., Chambers P., Man K., Dodwell D., Wang Z., Patel A., Pickwell-Smith B., Wei L.